


# Deep learning using tumor HLA peptide mass spectrometry datasets improves neoantigen identification

*Bulik-Sullivan et al.*

*Presented by Wesley Wei Qian*

# Introduction - neoantigens



## T-Cell receptors

T-cell receptors or TCRs are molecules on the surface of cancer fighting T cells that have the ability to interrogate individual cancer cells and see beneath the cell membrane.


## Neoantigens

Antigens are the unique molecules or proteins that help immune cells identify and fight cancer cells. Neoantigens are unique to each patient's tumor cells.

TCRs have the potential to be genetically modified so T cells can identify the neoantigen signature unique to one patient's cancer cells and then attack them.

We cannot just look at all the mutations in the tumor cell

- Lots of them
- Many processes are involved before the neoantigens are presented in the cell surface
- Different HLA/MHC proteins



---

**Given a peptide, what's the probability for it to present in the surface as a neoantigen?**




## Predicting the peptide-HLA binding affinity

- State of the art performs very well in binding affinity prediction
  - But lags behind in predicting actual presentation
  - Peptide-HLC binding is only one step in the pathway
- 
- Lots of information to consider in the process!


# Methods - what data/input/features to consider



# Methods - what data/input/features to consider



# Methods - what data/input/features to consider






# Methods - mass spectrometry




“Ionizing chemical species and sorting the ions based on their **mass-to-charge ratio**”.

As a fingerprints to identify molecules/peptides.




# Methods - what data/input/features to consider




# Methods - what data/input/features to consider


Positive Label! So what about Negative Label?




# Methods - what data/input/features to consider




# Methods - what data/input/features to consider






# Methods - neural network is a function approximator easy to be trained



# Methods - final prediction




$\Pr(\text{peptide } i \text{ presented by allele } k)$

$$= \text{sigmoid} \left\{ \begin{aligned} &NN_k(\text{peptide}_i) + NN_{\text{flanking}}(\text{flanking}_i) \\ &+ NN_{\text{RNA}}(\log(\text{TPM}_i)) + \alpha_{\text{sample}(i)} + \beta_{\text{protein}(i)} \end{aligned} \right\}$$

$$\Pr(\text{peptide } i \text{ presented}) = \sum_{k=1}^m a_k^i \times \Pr(\text{peptide } i \text{ presented by allele } k)$$



# Methods - final prediction



$\Pr(\text{peptide } i \text{ presented by allele } k)$


$$= \text{sigmoid} \left\{ \begin{aligned} &NN_k(\text{peptide}_i) + NN_{\text{flanking}}(\text{flanking}_i) \\ &+ NN_{\text{RNA}}(\log(\text{TPM}_i)) + \alpha_{\text{sample}(i)} + \beta_{\text{protein}(i)} \end{aligned} \right\}$$

$$\Pr(\text{peptide } i \text{ presented}) = \sum_{k=1}^m a_k^i \times \Pr(\text{peptide } i \text{ presented by allele } k)$$





$$\text{Loss}(i) = -\log\left(\text{Bernoulli}\left(y_i \mid \text{Pr}(\text{peptide } i \text{ presented})\right)\right)$$



# Results - different HLA indeed learns some pattern in the peptide sequence





# Results - benchmarks





# Results - evaluation metric





# Results - peptide presentation prediction performance



# Results - it performs very well





# Results - it performs very well









# Results - actual t-cell recognition




# Results - it against performs very well




# Results - it against performs very well




# Results - neoantigen identification in real cancer patient




# Results - surface formation units



# Results - there are some promising signals



# Results - there are some promising signals





- Incorporating peptide-extrinsic features helps
- Better model the peptide sequence with different alleles type helps
- Lot's of work go into the data collection (clean up, clinical experiments etc.) to make this an interesting paper.
- Extend this work to HLA Class II binding
- Consider the TCR binding or T-Cell precursor information (i.e. modeling more information in the pathway)
- Better neural network model?





- Incorporating peptide-extrinsic features helps
- Better model the peptide sequence with different alleles type helps
- Lot's of work go into the data collection (clean up, clinical experiments etc.) to make this an interesting paper.
- Extend this work to HLA Class II binding
- Consider the TCR binding or T-Cell precursor information (i.e. modeling more information in the pathway)
- Better neural network model?



- Incorporating peptide-extrinsic features helps
- Better model the peptide sequence with different alleles type helps
- Lot's of work go into the data collection (clean up, clinical experiments etc.) to make this an interesting paper.
- Extend this work to HLA Class II binding
- Consider the TCR binding or T-Cell precursor information (i.e. modeling more information in the pathway)
- Better neural network model?

# Q&A

---